Heart Failure

 

Declining Risk of Sudden Death in Heart Failure

Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps.

Patient selection in heart failure with preserved ejection fraction clinical trials

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction

Decongestion in acute heart failure. 

Learning from recent trials and shaping the future of acute heart failure trials. 

Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition

 

CKD

Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints

 

Cardiovascular non-drug therapies

Neural modulation for hypertension and heart failure.

Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction

Design Considerations for Clinical Trials of Autonomic Modulation Therapies Targeting Hypertension and Heart Failure.

Current challenges for clinical trials of cardiovascular medical devices.

Trials of implantable monitoring devices in heart failure: which design is optimal?

 

Diabetes

Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment versus risk aversion

 

Atherosclerosis

Atherosclerosis: Recent trials, new targets and future directions

 

Biomarkers/Cell Therapies

Charting a Roadmap for Heart Failure Biomarker Studies

Biomarker-guided therapies in heart failure: a forum for unified strategies.

Similarities and differences in design considerations for cell therapy and pharmacologic cardiovascular clinical trials.

 

CV Research

Implications of geographical variation on clinical outcomes of cardiovascular trials.

Globalization of cardiovascularclinical research: the balance between meeting medical needs and maintaining scientific standards.

 

CV Drug Trials

Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. 

The past, present and future of renin-angiotensin aldosterone system inhibition.

Agents with vasodilator properties in acute heart failure: how to design successful trials

New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval.

Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties.

Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries.

Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future